




Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.3. Reserve group antibiotics

| | | EMLc | ATC codes: J01XX08 |
|--------------------------|---|------------------|--------------------|
| Indication | Other specified bacterial diseases | ICD11 code: 1C4Y | |
| INN | Linezolid | | |
| Medicine type | Chemical agent | | |
| Antibiotic groups | R RESERVE | | |
| List type | Complementary (EML) (EMLc) | | |
| Formulations | Parenteral > General injections > IV: 2 mg per mL in 300 mL bag Oral > Liquid: 100 mg per 5 mL powder for oral liquid Oral > Solid: 400 mg tablet ; 600 mg tablet | | |
| EML status history | First added in 2017 (TRS 1006) Removed in 2019 (TRS 1021) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Read more about patents .  | | |
| Wikipedia | Linezolid  | | |
| DrugBank | Linezolid  | | |

Summary of evidence and Expert Committee recommendations

As part of the review of the AWaRe classification and EML listing of antibiotics, the Expert Committee recommended selected Reserve group antibiotics be listed as individual medicines on the WHO Model Lists when they have a favourable benefit-risk profile and proven activity against "Critical Priority" or "High Priority" pathogens as identified by the WHO Priority pathogens list. Refer to the 2019 recommendations for new indications for linezolid on the EML and EMLc.

[Expert Committee report](#) 
